PNOC Study in Childhood Brain Cancer Enrols First Patient
PNOC022 includes Kazia's investigational drug, paxalisib among the experimental arms and is expected to provide valuable data on the potential use of the drug in this highly aggressive form of childhood brain cancer.
- PNOC022 includes Kazia's investigational drug, paxalisib among the experimental arms and is expected to provide valuable data on the potential use of the drug in this highly aggressive form of childhood brain cancer.
- Diffuse intrinsic pontine glioma (DIPG) is the most common of a group of childhood brain cancers known as diffuse midline gliomas (DMGs).
- The PNOC022 study is sponsored by the Pacific Pediatric Neuro-Oncology Consortium (PNOC), an international consortium focused on the development of new therapies for brain cancer.
- The lead investigator, Professor Sabine Mueller, is a board-certified neurologist and paediatric neuro-oncologist whose research focuses on novel therapies in childhood brain cancer.